SCHEMBL28158643

SCHEMBL28158643

COc1cc(OC)c2cncnc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.55
PDGFRA P16234 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
MAPT P10636 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 1/20 0.55
EGFR P00533 6/20 0.53
LCK P06239 4/20 0.43
SRC P12931 2/20 0.41
FGFR4 P22455 1/20 0.39
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31143861 0.81 EGFR (0.46) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL16537257 0.74 PDGFRB (0.57) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL16536235 0.74 PDGFRB (0.57) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL2201806 0.73 HPGDS (0.57) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL29831692 0.73 EGFR (0.47) PDGFRAALDH1A1CYP1A2CYP3A4ALOX15
SCHEMBL28231820 0.72 PDGFRB (0.46) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL24393041 0.71 SRC (0.50) PDGFRBPDGFRAMEN1KMT2AALDH1A1
SCHEMBL27980378 0.71 SYK (0.64) PDGFRBPDGFRAMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL5736824 0.71 EGFR (0.46) PDGFRAALDH1A1CYP1A2CYP3A4HPGD
SCHEMBL3652915 0.71 PDGFRB (1.00) PDGFRBPDGFRAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 US disclosed
CN-108358856-B It is a kind of prevent and treat peptic ulcer drug with and its preparation method and application 牡丹江医学院 2019-09-13 CN disclosed
CN-108358856-A It is a kind of prevention peptic ulcer drug with and its preparation method and application 牡丹江医学院 2018-08-03 CN disclosed
CN-107252429-A New antiinflammatory 雷斯韦洛吉克斯公司 2017-10-17 CN disclosed
CN-102458405-B Novel anti-inflammatory agents 雷斯韦洛吉克斯公司 2017-06-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 PDGFRB 672/4885PDGFRA 958/4885MEN1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.